A Phase 2 interventional study of ARO-APOC3 in Dyslipidemias, sponsored by Arrowhead Pharmaceuticals. Completed at 60 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-12.
Sponsored by Arrowhead Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Dyslipidemias with a site in United States — 23 open to participants now, 34 under way, 6 of them phase 3. Dyslipidemias · United States.
Among the 349 studies in Dyslipidemias with a site in United States, this one is the 61st largest by enrollment of the 316 interventional ones that give a count, is one of 10 that started in 2022, is one of 66 in phase 2, and was the 291st registered.
1,249 studies on the registry are indexed under Dyslipidemias; 177 are open to participants now.
Browse Dyslipidemias studies →23 of the 349 studies in Dyslipidemias with a site in United States are open now. Recruiting first, the newest first:
Arrowhead Pharmaceuticals · Sites in United States, Denmark, Poland
Ages 12–17
University of Connecticut · Sites in United States
Ages 18–64
University of Georgia · Sites in United States
Ages 25–75 · Healthy volunteers
AstraZeneca · Sites in United States
Ages 18–70
Novartis Pharmaceuticals · Sites in United States, Austria, China and 8 more countries
Ages 2–11
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 112 Dyslipidemias studies recruiting now, 55 (49%) set no upper age limit and 36 (32%) stop at 75 or younger; 11 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 47 · Phase 2 75 · Phase 3 76 · Phase 4 23
First in 1976; this study’s year is marked. 10 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 418 is above the median of 100 across 986 interventional studies indexed under Dyslipidemias.
Median enrollment 105 across the 316 interventional studies, 140 across the 31 observational. Of the 299 that completed or were terminated, 125 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
170 of 349 have an industry lead sponsor. The 10 most frequent:
Arrowhead Pharmaceuticals is the lead sponsor of 50 studies on the registry; 9 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 12 (50%) have results posted.
Arrowhead Pharmaceuticals has 5 studies filed under Dyslipidemias — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyslipidemias with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06496243NewAmsterdam PharmaImpact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels | 2026-11 |
| NCT06382298University of GeorgiaCottonseed Oil Versus Matched PUFA Effects | 2026-12 |
| NCT06300450Brigham and Women's HospitalRandomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy | 2026-12-28 |
Add all 13 to your calendar (.ics) → With an account.
Among the 349 studies in Dyslipidemias with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open-label extension of the parent studies AROAPOC3-2001 and AROAPOC3-2002. Adult participants with dyslipidemia who completed the blinded 12-month period from either parent study and continued to meet eligibility criteria had the option to be enrolled into this study. Eligible enrolled participants initially received open-label ARO-APOC3 every three or six months at the assigned dose level of the parent study until a final dose of 25 mg was selected, at which point all participants transitioned to the selected dosing regimen of 25 mg every 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
1 dose of ARO-APOC3 by subcutaneous (sc) injection every 3 months
Drug: ARO-APOC3
ARO-APOC3 Injection
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Time frame: Through 24 months
Change from Baseline in Fasting Triglycerides (TG) Over Time
Time frame: Through 24 months
Percent Change from Baseline in Fasting TG Over Time
Time frame: Through 24 months
Change from Baseline in Apolipoprotein (Apo) C-III Over Time
Time frame: Through 24 months
Percent Change from Baseline in ApoC-III Over Time
Time frame: Through 24 months
Change from Baseline in Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) Over Time
Time frame: Through 24 months
Percent Change from Baseline in Fasting Non-HDL-C Over Time
Time frame: Through 24 months
Change from Baseline in Fasting High-Density Lipoprotein-Cholesterol (HDL-C) Over Time
Time frame: Through 24 months
Percent Change from Baseline in Fasting HDL-C Over Time
Time frame: Through 24 months
Change from Baseline in Fasting Total Apolipoprotein B (ApoB) Over Time
Time frame: Through 24 months
Percent Change from Baseline in Fasting Total ApoB Over Time
Time frame: Through 24 months
Change from Baseline in Fasting Low-Density Lipoprotein-Cholesterol (LDL-C) Over Time Using Ultracentrifugation
Time frame: Through 24 months
Percent Change from Baseline in Fasting LDL-C Over Time Using Ultracentrifugation
Time frame: Through 24 months
Plan to share: No
Ran from Jul 2022 to primary completion in Sep 2025, 38 months.
Of 35 industry-sponsored phase 2 interventional studies under Dyslipidemias, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 38 months is above that.
Counting every sponsor, half of 43 studies reached it within 13 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Plozasiran